T2 biosystems, inc. (TTOO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities
Net loss

-59,006

-51,153

-62,428

-54,804

-

-

-

-

Net loss

-

-

-

-

-45,290

-31,390

-20,610

-14,455

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,197

2,449

2,940

2,280

1,465

691

584

571

Amortization of operating lease right-of-use assets

1,445

-

-

-

-

-

-

-

Stock-based compensation expense

5,458

9,897

4,790

4,848

4,168

1,653

578

403

(Gain) loss on disposal of property and equipment

3

-26

-

-

-

-

-

-

Change in fair value of derivative instrument

-283

96

-2,238

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-112

-

-

-

-

Impairment of property and equipment

-

683

2,571

-

-

-

-

-

Non-cash interest expense

2,407

2,216

2,710

564

354

112

44

46

Noncash warrant expense

-

-

-

-

-

-

-

81

Change in fair value of warrants

-

-

-

-

-

1

530

-132

Loss on disposal of asset

-

-

-

-

-

-

-6

-

Deferred rent

-

217

115

250

119

-5

5

15

Changes in operating assets and liabilities:
Accounts receivable

1,039

1,319

140

-42

168

201

-

-

Prepaid expenses and other assets

98

570

-125

-68

-190

1,217

138

2

Inventories

914

1,089

110

120

568

115

-

-

Accounts payable

2,960

121

-314

-61

177

-208

372

-88

Accrued expenses and other liabilities

3,708

-279

724

580

260

2,405

-

-

Deferred revenue

-499

-807

-709

299

-

-

-

-

Operating lease liabilities

-2,260

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-

-

-

-

-

-

586

258

Deferred revenue

-

-

-

-

2,066

80

-

-

Net cash used in operating activities

-45,361

-40,138

-47,718

-46,442

-37,465

-

-

-

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-

-28,184

-18,053

-13,303

Purchases and manufacture of property and equipment

761

593

2,476

5,487

7,974

2,084

513

283

Decrease in restricted cash

-

-

-

-

80

-

80

-

Net cash used in investing activities

-761

-593

-2,476

-5,487

-7,894

-

-

-

Cash flows from financing activities
Net cash used in investing activities

-

-

-

-

-

-2,084

-433

-283

Proceeds from issuance of common stock and stock options exercises, net

-

-

-

-

-

153

-

-

Proceeds from issuance of common stock and stock option exercises, net

-

-

-

-

-

-

-

1

Proceeds from issuance of redeemable convertible preferred stock, net

-

-

-

-

-

-

39,768

-

Proceeds from issuance of common stock and stock option exercises, net

-

-

-

1,018

1,804

-

55

-

Proceeds from issuance of common stock in public offering, net of offering costs

6,650

49,237

18,640

-385

33,677

58,089

-

-

Proceeds from issuance of shares from employee stock purchase plan and stock option exercises

582

1,967

1,059

-

-

-

-

-

Principal repayments of finance leases

882

1,547

1,194

-

-

-

-

-

Proceeds from private investment in public equity

-

-

-

39,723

-

-

-

-

Proceeds from notes payable, net of issuance costs

-

-

-

43,803

10,000

19,714

-

4,924

Principal repayments of note payable

-

-

-

32,404

309

4,037

848

374

Net cash provided by (used in) financing activities

6,350

49,657

18,505

51,755

45,172

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-39,772

8,926

-31,689

-174

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash at end of period
Net cash provided by financing activities

-

-

-

-

-

73,919

38,975

4,551

Net decrease in cash and cash equivalents

-

-

-

-

-187

43,651

20,489

-9,035

Supplemental disclosures of cash flow information
Cash paid for interest

4,659

3,786

3,959

2,732

-

-

-

-

Cash paid for interest

-

-

-

-

1,506

515

345

101

Supplemental disclosures of noncash activities
Transfer of T2 owned instruments and components to (from) inventory

-8

244

431

-

-

-

-

-

Change in fair value of warrants issued and modified

924

-

-

-

-

-

-

-

Leasehold improvements paid by landlord

-

-

-

-

1,268

121

-

-

Transfer from other liabilities to accrued expenses and other current liabilities

2,400

1,400

585

-

-

-

-

-

Right-of-use assets obtained in exchange for new operating lease liabilities

4,805

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

107

80

189

82

247

128

-

-

Public offering costs unpaid at year end

-

-

59

-

420

-

-

-

Accretion of Series A-1, A-2, B, C, D and E redeemable convertible preferred stock to redemption value

-

-

-

-

-

4,570

-

-

Conversion of redeemable and convertible preferred stock to common stock

-

-

-

-

-

117,383

-

-

Conversion of preferred warrants to common stock

-

-

-

-

-

1,226

-

-

Accretion of Series A-1, A-2, B, C, D and E redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

6,908

4,412

Warrants issued in connection with debt

-

-

-

-

-

-

-

64